5-cyano-N’-hydroxypicolinimidamide | 453565-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-cyano-N’-hydroxypicolinimidamide
• 英文别名: 5-cyano-N'-hydroxypyridine-2-carboximidamide；5-cyanopyrid-2-ylamidoxime；2-Pyridinecarboximidamide, 5-cyano-N-hydroxy-
• CAS: 453565-48-5
• 化学式: C₇H₆N₄O
• mdl: MFCD20724464
• 分子量: 162.151
• InChiKey: CZEOZNIOPJZBMW-UHFFFAOYSA-N

物化性质

• 沸点：
  351.5±52.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-cyano-N’-hydroxypicolinimidamide 在 盐酸 、 碳酸氢钠 、 三氟乙酸 、 sodium nitrite 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 23.5h， 生成 6-(5-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)isoxazol-3-yl)nicotinonitrile
  参考文献：
  名称：

  [EN] FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS
  [FR] FLUORO-[1,3]OXAZINES EN TANT QU'INHIBITEURS DE BACE1

  摘要：

  本发明提供一种具有BACE1抑制活性的化合物I的公式，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病方面是有用的。

  公开号：

  WO2016001266A1
• 作为产物：
  描述：

  2,5-二氰基吡啶 在 盐酸羟胺 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 0.08h， 以59.9%的产率得到5-cyano-N’-hydroxypicolinimidamide
  参考文献：
  名称：

  Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development

  摘要：

  AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.100

文献信息

• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1379525A2

  公开（公告）日：2004-01-14
• US6660753B2
  申请人：——

  公开号：US6660753B2

  公开（公告）日：2003-12-09
• US7112595B2
  申请人：——

  公开号：US7112595B2

  公开（公告）日：2006-09-26
• [EN] HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES HETEROPOLYCYCLIQUES ET LEUR UTILISATIONS EN TANT QU'ANTAGONISTES DES RECEPTEURS METABOTROPIQUES DU GLUTAMATE
  申请人：NPS PHARMA INC

  公开号：WO2002068417A2

  公开（公告）日：2002-09-06

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Method of preparing the compounds also are disclosed.